Organon Pulls Plug on PCOS Treatment, Signaling Troubled Acquisition
Organon & Co. has discontinued development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS), marking a significant setback for KDventures' 2021 acquisition of Forendo Pharmaceuticals. The decision represents the termination of both drug candidates from the portfolio company purchase, following the earlier discontinuation of OG-6219 for endometriosis in July 2025. As a result, KDventures will write off its entire remaining book value of potential additional purchase considerations tied to the acquisition.
This double discontinuation underscores the inherent risks in biotech M&A activity, where promising preclinical assets often fail to translate into viable therapeutics. The failed PCOS candidate had been in preclinical development stages when Organon acquired Forendo, but apparently failed to meet internal development thresholds or demonstrate sufficient commercial potential to justify continued investment. The move leaves no active development programs from the original Forendo portfolio intact at Organon.
The Forendo Acquisition Unravels
When Organon acquired Forendo in 2021, the deal was expected to strengthen the company's women's health pipeline, a strategically important therapeutic area for the pharmaceutical giant. The Forendo portfolio included multiple candidates targeting gynecological conditions, a disease area with significant unmet medical needs and substantial market opportunities. PCOS alone affects approximately 8-13% of women of reproductive age worldwide, making it a potentially lucrative indication for successful treatments.
However, the acquisition has yielded disappointing results:
- OG-6219 (endometriosis candidate) discontinued July 2025
- PCOS candidate discontinued in current period
- Complete portfolio write-off of remaining contingent considerations
- Zero active programs remaining from original Forendo acquisition
The contingent consideration component of the acquisition deal—typically structured to incentivize achievement of development milestones—will now be fully written off. This means KDventures, which held equity in Forendo prior to the Organon acquisition, will realize zero value from any earnout provisions tied to clinical development progress.
Market Context: Women's Health Remains Challenging
The failure of Forendo's assets within the Organon pipeline reflects broader challenges in women's health drug development. While conditions like PCOS and endometriosis represent significant therapeutic needs, they have proven difficult to address with pharmacological solutions. Drug development timelines are lengthy, failure rates remain high, and commercial viability depends on multiple factors including efficacy, safety profile, and competitive landscape.
Organon, which separated from Merck in 2021 specifically to focus on women's health and biosimilars, faces heightened pressure to demonstrate its standalone viability. The company has made substantial commitments to women's health development, making continued asset failures problematic for its strategic narrative. PCOS treatment remains an active area of pharmaceutical development, with several companies pursuing both hormonal and non-hormonal approaches.
The women's health sector has attracted significant investment over the past decade, with venture capital and major pharmaceutical companies recognizing underserved patient populations. However, execution remains challenging, and multiple organizations have faced setbacks in bringing novel therapies to market. The discontinuation of two Forendo candidates suggests either fundamental scientific challenges with the approach or competing priorities in Organon's development portfolio.
Investor Implications: Asset Quality and M&A Risk
For KDventures investors, this announcement crystallizes the risks inherent in early-stage biotech investing. Venture capital firms frequently structure portfolio company sales to strategic acquirers with earnout provisions designed to align incentives and provide upside if programs succeed. When acquisitions result in total portfolio write-offs, it erases expectations for those contingent payments.
The implications for Organon ($OGN) shareholders are more nuanced. While the discontinuations represent failed development bets, they also demonstrate disciplined capital allocation—terminating programs that don't meet commercial thresholds rather than investing further capital in low-probability assets. However, the loss of an entire acquired portfolio represents a strategic misstep in portfolio planning.
This situation highlights several investment lessons:
- Preclinical-stage assets carry extreme development risk even when acquired by well-capitalized pharma companies
- Women's health remains a challenging therapeutic area despite significant market opportunity
- Contingent consideration structures may overestimate probability-weighted success rates
- M&A integration failures can eliminate value quickly when programs don't progress
For institutional investors evaluating biotech M&A deals, the Forendo acquisition serves as a cautionary tale about overpaying for early-stage assets or overestimating internal execution capabilities.
Looking Forward: Implications for Future M&A
The complete failure of the Forendo portfolio may influence Organon's future acquisition strategy and risk tolerance. Companies that experience major acquisition failures often become more selective in subsequent dealmaking, focusing on assets with more clinical validation or lower integration risk. For the broader biotech venture ecosystem, this underscores the importance of realistic exit multiples for preclinical-stage companies.
KDventures and other investors who participated in Forendo financing rounds will need to account for the total loss in their fund performance metrics. This type of outcome, while disappointing, is not uncommon in venture capital, where power laws typically mean a small number of winners compensate for numerous failures. However, the complete elimination of contingent consideration upside represents a worst-case scenario for acquisition-based exits.
The discontinuation of both Forendo programs marks the effective end of this acquisition as a strategic value creator for Organon. Moving forward, the company must demonstrate success with other women's health initiatives to justify its strategic focus and standalone viability as a specialized pharmaceutical company.